Maria Elisa Mancuso: During Day 2 of the Annual EHC Conference We Discussed Very Rare Bleeding Disorders!
Maria Elisa Mancuso, Senior Hematology Consultant at Humanitas Research Hospital, shared on LinkedIn:
”During Day 2 of the Annual EHC Conference in Vienna we discussed very rare bleeding disorders as fibrinogen defects (thanks to Alessandro Casini) and the “newly recognized” group of Bleeding Disorders of Unknown Cause – BDUC (thanks to Johanna Gebhart).
Congratulations to Dominik Cepic for is wonderful overview and passionate advocacy for hemophilia B with inhibitors as “rare among rares”.
The SLAM session shed lights to many important issues as orthopedic evaluation and care of arthropathy, treatment of PUPs, pain and ITI.
During the session dedicated to gene therapy real world experience (Wolfgang Miesbach), struggles in procurement and reimbursement (Gaetan Duport) and new non-AAV mediated gene therapies (Paul Batty) were discussed.
Finally the day was beautifully close by the energy of the youth debates.”

More from EHC 2025 featured in Hemostasis Today.
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance
-
Nov 20, 2026, 11:33Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion
-
Nov 20, 2026, 11:28Stéphanie Forté: Bringing Cutting-Edge Genomic and Proteomic Tools to Sickle Cell Disease Patients
-
Nov 20, 2026, 11:19EHC Urges Equal Early Diagnosis for Bleeding Disorders
-
Nov 20, 2026, 11:14Pushpinder Singh: How Do We Know if Haemodialysis is Effective?
-
Nov 20, 2026, 11:09Neel Patel: Honoured to Serve Across Five Faculty Roles at Hematocon 2026
-
Nov 20, 2026, 11:03Alok Khorana: First FXI Inhibitor Approved in the US
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA